TWI633103B - 選擇性ｃｄｋ４／６抑制劑之固態形式 - Google Patents

選擇性ｃｄｋ４／６抑制劑之固態形式 Download PDF

Info

Publication number
TWI633103B
TWI633103B TW103105287A TW103105287A TWI633103B TW I633103 B TWI633103 B TW I633103B TW 103105287 A TW103105287 A TW 103105287A TW 103105287 A TW103105287 A TW 103105287A TW I633103 B TWI633103 B TW I633103B
Authority
TW
Taiwan
Prior art keywords
free base
compound
ppm
particle size
methyl
Prior art date
Application number
TW103105287A
Other languages
English (en)
Chinese (zh)
Other versions
TW201444834A (zh
Inventor
布萊恩 查可
南森 艾德
Original Assignee
輝瑞股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50151343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI633103(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 輝瑞股份有限公司 filed Critical 輝瑞股份有限公司
Publication of TW201444834A publication Critical patent/TW201444834A/zh
Application granted granted Critical
Publication of TWI633103B publication Critical patent/TWI633103B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW103105287A 2013-02-21 2014-02-18 選擇性ｃｄｋ４／６抑制劑之固態形式 TWI633103B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361767761P 2013-02-21 2013-02-21
US61/767,761 2013-02-21

Publications (2)

Publication Number Publication Date
TW201444834A TW201444834A (zh) 2014-12-01
TWI633103B true TWI633103B (zh) 2018-08-21

Family

ID=50151343

Family Applications (2)

Application Number Title Priority Date Filing Date
TW103105287A TWI633103B (zh) 2013-02-21 2014-02-18 選擇性ｃｄｋ４／６抑制劑之固態形式
TW106131041A TWI670269B (zh) 2013-02-21 2014-02-18 選擇性ｃｄｋ４／６抑制劑之固態形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW106131041A TWI670269B (zh) 2013-02-21 2014-02-18 選擇性ｃｄｋ４／６抑制劑之固態形式

Country Status (24)

Country Link
US (2) US20160002223A1 (https=)
EP (2) EP2958916B1 (https=)
JP (3) JP6381016B2 (https=)
KR (2) KR20150107872A (https=)
CN (3) CN105008357A (https=)
AR (1) AR094842A1 (https=)
AU (1) AU2014220354B2 (https=)
BR (1) BR112015019508A8 (https=)
CA (1) CA2900322C (https=)
CY (2) CY1120734T1 (https=)
DK (2) DK2958916T3 (https=)
ES (2) ES2869277T3 (https=)
HK (2) HK1211032A1 (https=)
HU (2) HUE040434T2 (https=)
IL (1) IL240277B (https=)
MX (2) MX386473B (https=)
PL (2) PL3431475T3 (https=)
PT (2) PT3431475T (https=)
RU (1) RU2619944C2 (https=)
SG (1) SG11201505680RA (https=)
SI (2) SI2958916T1 (https=)
TR (1) TR201816077T4 (https=)
TW (2) TWI633103B (https=)
WO (1) WO2014128588A1 (https=)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100451T1 (it) 2012-07-11 2021-09-14 Blueprint Medicines Corp Inibitori del recettore di crescita dei fibroblasti
SI2958916T1 (sl) 2013-02-21 2018-11-30 Pfizer Inc. Trdne oblike selektivnih zaviralcev CDK4/6
CA2928042C (en) 2013-10-25 2022-05-10 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US20170240543A1 (en) * 2014-08-14 2017-08-24 Sun Pharmaceutical Industries Limited Crystalline forms of palbociclib
WO2016030439A1 (en) * 2014-08-28 2016-03-03 Ratiopharm Gmbh Method of producing palbociclib and pharmaceutical compositions comprising the same
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
WO2016090257A1 (en) * 2014-12-05 2016-06-09 Crystal Pharmatech Inc. Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
WO2016092442A1 (en) * 2014-12-08 2016-06-16 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline forms of palbociclib acetate
CN104610254B (zh) * 2015-01-26 2017-02-01 新发药业有限公司 一种帕博赛布的低成本制备方法
CZ201589A3 (cs) 2015-02-11 2016-08-24 Zentiva, K.S. Pevné formy soli Palbociclibu
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
EP3078663A1 (en) 2015-04-09 2016-10-12 Sandoz Ag Modified particles of palbociclib
CN106117199A (zh) * 2015-05-04 2016-11-16 江苏恒瑞医药股份有限公司 一种细胞周期蛋白依赖性激酶抑制剂的二羟乙基磺酸盐、其结晶形式及其制备方法
MX376083B (es) * 2015-06-04 2025-03-07 Pfizer Formas de dosificacion solidas de palbociclib.
CN106317053A (zh) * 2015-06-29 2017-01-11 北大方正集团有限公司 一种帕博昔布晶型a的制备方法
CN106397431A (zh) * 2015-07-28 2017-02-15 苏州国匡医药科技有限公司 一种抗肿瘤药物的新晶型及其制备方法和用途
CN105153149B (zh) * 2015-07-29 2017-09-19 江苏中邦制药有限公司 一种选择性激酶抑制剂Palbociclib的制备方法
ES2741958T3 (es) 2015-08-05 2020-02-12 Ratiopharm Gmbh Nueva forma cristalina y aductos de ácido acético de palbociclib
CN105085517B (zh) * 2015-08-06 2016-11-23 天津华洛康生物科技有限公司 一种结晶型帕博西尼游离碱水合物及其制备方法
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
EP3362455A1 (en) 2015-10-16 2018-08-22 AbbVie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
CN106608876B (zh) * 2015-10-21 2018-06-19 新发药业有限公司 一种高纯度帕博西尼的制备方法
HU230962B1 (hu) 2015-10-28 2019-06-28 Egis Gyógyszergyár Zrt. Palbociclib sók
CN106632311B (zh) * 2015-11-02 2021-05-18 上海科胜药物研发有限公司 一种帕博西尼晶型a和晶型b的制备方法
CN106831759A (zh) * 2015-12-03 2017-06-13 上海星泰医药科技有限公司 帕布昔利布及其中间体的制备方法
CN105541832A (zh) * 2015-12-15 2016-05-04 南京艾德凯腾生物医药有限责任公司 一种羟乙基磺酸盐帕布昔利布的制备方法
WO2017115315A1 (en) * 2015-12-30 2017-07-06 Dr. Reddy's Laboratories Limited Solid forms of palbociclib
CN105524059A (zh) * 2016-01-06 2016-04-27 北京修正创新药物研究院有限公司 一种帕波西比杂质的制备方法
GB201601329D0 (en) 2016-01-25 2016-03-09 Mohammad Mohammad A Inverse gas chromatography standard solutions, device and method
WO2017130219A1 (en) 2016-01-25 2017-08-03 Mylan Laboratories Limited Amorphous solid dispersion of palbociclib
WO2017145054A1 (en) * 2016-02-24 2017-08-31 Lupin Limited Modified particles of crystalline palbociclib free base and process for the preparation thereof
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN106336411B (zh) * 2016-04-27 2018-03-06 上海医药集团股份有限公司 Cdk4/6抑制剂帕博西尼高纯度原料药的制备工艺及用途
CN109661393A (zh) * 2016-05-08 2019-04-19 上海诚妙医药科技有限公司 帕布昔利布的新晶型及其制备方法及其用途
CN105924439B (zh) * 2016-06-24 2017-11-24 石家庄海瑞药物科技有限公司 一种帕布昔利布的制备方法
CN106146494B (zh) * 2016-06-29 2018-02-06 重庆华邦制药有限公司 用于制备帕布昔利布a型晶的溶剂及制备方法
WO2018009735A1 (en) * 2016-07-07 2018-01-11 Plantex Ltd. Solid state forms of palbociclib dimesylate
CN106220627A (zh) * 2016-07-31 2016-12-14 合肥远志医药科技开发有限公司 一种高纯度帕布昔利布的工业化制备方法
CN106220626A (zh) * 2016-07-31 2016-12-14 合肥远志医药科技开发有限公司 一种帕布昔利布的多晶型及其制备方法
CN109803968A (zh) 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
WO2018065999A1 (en) 2016-10-07 2018-04-12 Mylan Laboratories Limited Novel polymorph of an intermediate for palbociclib synthesis
CA3040815C (en) 2016-10-20 2021-07-20 Steven Martin Evans Anti-proliferative agents for treating pah
WO2018073574A1 (en) 2016-10-20 2018-04-26 Cipla Limited Polymorphic forms of palbociclib
CN108017630B (zh) * 2016-10-31 2022-10-11 上海创诺制药有限公司 一种小比表面积帕博西尼游离碱的制备方法
EP3541389A1 (en) 2016-11-16 2019-09-25 Pfizer Inc Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
CN108117550B (zh) * 2016-11-29 2020-08-14 上海医药工业研究院 吡啶并[2,3-d]嘧啶类化合物的制备方法
EP3556758B1 (en) 2016-12-16 2024-07-17 Cstone Pharmaceuticals (Suzhou) Co., Ltd. 1,2-dihydro-1,6-naphthyridin-2-one derivatives as cdk4/6 inhibitors
EP3612230A4 (en) * 2017-04-21 2020-12-16 Alnova Pharmaceuticals, Ltd. PALBOCICLIB COMPOSITIONS AND RELATED METHODS
CN108864078B (zh) * 2017-05-10 2021-10-15 江苏豪森药业集团有限公司 帕博西尼晶型b的制备方法
EP3652318A1 (en) 2017-07-11 2020-05-20 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
WO2019020715A1 (en) 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING PALBOCICLIB
RU2020111019A (ru) 2017-08-18 2021-09-20 Трагара Фармасьютикалз, Инк. Полиморфная форма tg02
AU2018354972B2 (en) 2017-10-27 2021-07-08 Fresenius Kabi Oncology Ltd. An improved process for the preparation of ribociclib and its salts
CN109897034A (zh) * 2017-12-07 2019-06-18 南京卡文迪许生物工程技术有限公司 一种高纯度晶型a帕布昔利布及其制备方法和药物组合物
MX2020007312A (es) 2018-01-08 2021-01-08 G1 Therapeutics Inc Regimenes de dosificacion superior de g1t38.
CN108586452A (zh) * 2018-01-12 2018-09-28 重庆市碚圣医药科技股份有限公司 一种帕博西尼中间体的合成方法
EP3758753A1 (en) 2018-02-27 2021-01-06 Pfizer Inc Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
CN108299422B (zh) * 2018-02-28 2019-10-25 杭州福斯特药业有限公司 一种帕泊昔利布中间体的制备方法
ES2968899T3 (es) 2018-05-14 2024-05-14 Pfizer Formulación de la solución oral
CN108558745A (zh) * 2018-05-17 2018-09-21 苏州莱克施德药业有限公司 一种帕博西林中间体的合成方法
PL3802529T3 (pl) 2018-05-24 2024-03-25 Synthon B.V. Sposób wytwarzania palbocyklibu
CN112292379B (zh) * 2018-06-13 2022-03-04 基石药业（苏州）有限公司 吡啶并吡啶酮衍生物的盐型及晶型
EP3844276A2 (en) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
JP6952747B2 (ja) 2018-09-18 2021-10-20 ファイザー・インク がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
TWI857981B (zh) 2018-10-24 2024-10-11 美商伊凡克特治療公司 Ｍｎｋ抑制劑的結晶形式
CN109336886A (zh) * 2018-12-07 2019-02-15 重庆三圣实业股份有限公司 一种帕博西尼的制备方法及其产品
WO2020148635A1 (en) * 2019-01-17 2020-07-23 Pfizer Inc. Crystalline form of a cdk inhibitor
US20220125777A1 (en) 2019-02-01 2022-04-28 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
WO2020240360A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
AU2020281535A1 (en) 2019-05-24 2022-01-27 Merck Patent Gmbh Combination therapies using CDK inhibitors
CN110256424A (zh) * 2019-07-03 2019-09-20 武汉工程大学 一种帕博西尼关键中间体v的合成方法
IL320609A (en) 2019-08-26 2025-07-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
CN110551063A (zh) * 2019-10-17 2019-12-10 山东邹平大展新材料有限公司 一种合成5-(n-boc-哌嗪-1-基)吡啶-2-胺的方法
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
TW202216131A (zh) 2020-07-15 2022-05-01 美商輝瑞大藥廠 用於癌症治療之ｋａｔ６抑制劑方法及組合
EP4181919A1 (en) 2020-07-20 2023-05-24 Pfizer Inc. Combination therapy
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
CN112274493A (zh) * 2020-11-18 2021-01-29 石药集团中奇制药技术（石家庄）有限公司 一种哌柏西利胶囊的制备方法
CN112457311B (zh) * 2020-12-04 2022-07-12 江苏豪森药业集团有限公司 一种含有氯溴吡咯嘧啶酮结构化合物的制备方法
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
CN112661753B (zh) * 2020-12-29 2022-06-03 山东铂源药业股份有限公司 一种帕布昔利布中间体的制备方法
CN112778303A (zh) * 2020-12-31 2021-05-11 武汉九州钰民医药科技有限公司 Cdk4/6激酶抑制剂shr6390的制备方法
CN112898299B (zh) * 2021-01-26 2021-11-26 山东铂源药业有限公司 一种帕布昔利布中间体的制备方法
WO2022266070A1 (en) 2021-06-14 2022-12-22 Preh Holding, Llc Connected body surface care module
CN117396208A (zh) 2021-07-16 2024-01-12 达纳－法伯癌症研究所公司 细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法
CN113845520A (zh) * 2021-09-09 2021-12-28 安徽皓元药业有限公司 一种帕布昔利布乳清酸盐及其制备方法
CN113999227A (zh) * 2021-11-26 2022-02-01 常州大学 一种帕博西尼中间体的制备方法
CA3240454A1 (en) 2021-12-10 2023-06-15 Lacey Morgan LITCHFIELD Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibito
WO2023111810A1 (en) 2021-12-14 2023-06-22 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023114264A1 (en) 2021-12-15 2023-06-22 Eli Lilly And Company Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
CN114195784A (zh) * 2021-12-29 2022-03-18 斯坦德标准技术研究(湖北)有限公司 帕博西尼有关物质及其制备方法和应用
EP4302755B1 (en) 2022-07-07 2025-08-20 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing an amino acid
EP4302832A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing glucono delta lactone
WO2024023703A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
WO2024049926A1 (en) 2022-08-31 2024-03-07 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
KR20250105413A (ko) 2022-11-02 2025-07-08 페트라 파마 코포레이션 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제
WO2024133726A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024132652A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
EP4689660A1 (en) 2023-03-30 2026-02-11 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
CN121843694A (zh) 2023-09-06 2026-04-10 阿费克斯发展有限公司 用于治疗及预防口腔癌的组合物与方法
US20250177414A1 (en) 2023-12-04 2025-06-05 Genentech, Inc. Combination therapies for treatment of breast cancer
WO2025202854A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
WO2026025013A2 (en) 2024-07-26 2026-01-29 Pfizer Inc. Combination therapy using cdk4 inhibitors for cancer treatments

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1835951A (zh) * 2003-07-11 2006-09-20 沃尼尔·朗伯有限责任公司 选择性cdk4抑制剂的羟乙基磺酸盐
CN101001857A (zh) * 2002-01-22 2007-07-18 沃尼尔·朗伯有限责任公司 2－(吡啶－2－基氨基)－吡啶并[2,3－d]嘧啶－7－酮

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JPH11138004A (ja) * 1997-11-06 1999-05-25 Mitsui Chem Inc ニトリル水和用の銅触媒及びその調製方法
PL358271A1 (pl) * 2000-03-06 2004-08-09 Warner-Lambert Company 5-alkilopirydo[2,3-D]pirymidyny jako inhibitory kinazy tyrozyny
JP2004074041A (ja) * 2002-08-20 2004-03-11 Cabot Supermetal Kk フッ素の回収方法
JP2004149472A (ja) * 2002-10-31 2004-05-27 Sumitomo Chem Co Ltd 亜リン酸エステル類の結晶、及びその製造方法
CN1976921B (zh) * 2004-06-29 2013-08-21 蓝宝石治疗公司 (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
BRPI0716880A2 (pt) 2006-09-08 2013-10-15 Pfizer Prod Inc Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
EP2185559A1 (en) * 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
TW201014830A (en) * 2008-09-30 2010-04-16 Theravance Inc Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
DK2453894T3 (en) * 2009-07-15 2016-01-25 Theravance Biopharma R&D Ip Llc Crystalline free base of a biphenyl compound
BR112012006252A2 (pt) * 2009-09-20 2017-05-23 Abbott Lab "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
PH12013500934A1 (en) * 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
SI2958916T1 (sl) 2013-02-21 2018-11-30 Pfizer Inc. Trdne oblike selektivnih zaviralcev CDK4/6
US20170240543A1 (en) 2014-08-14 2017-08-24 Sun Pharmaceutical Industries Limited Crystalline forms of palbociclib

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001857A (zh) * 2002-01-22 2007-07-18 沃尼尔·朗伯有限责任公司 2－(吡啶－2－基氨基)－吡啶并[2,3－d]嘧啶－7－酮
CN1835951A (zh) * 2003-07-11 2006-09-20 沃尼尔·朗伯有限责任公司 选择性cdk4抑制剂的羟乙基磺酸盐

Also Published As

Publication number Publication date
HK1211032A1 (en) 2016-05-13
TW201803872A (zh) 2018-02-01
HUE054212T2 (hu) 2021-08-30
EP2958916A1 (en) 2015-12-30
ES2694787T3 (es) 2018-12-27
AU2014220354B2 (en) 2018-02-01
US20160002223A1 (en) 2016-01-07
EP3431475A1 (en) 2019-01-23
AR094842A1 (es) 2015-09-02
RU2015132371A (ru) 2017-03-29
WO2014128588A1 (en) 2014-08-28
CN105008357A (zh) 2015-10-28
JP2019116512A (ja) 2019-07-18
PT2958916T (pt) 2018-11-21
TW201444834A (zh) 2014-12-01
IL240277B (en) 2019-10-31
SI3431475T1 (sl) 2021-08-31
JP6524152B2 (ja) 2019-06-05
MX2015010858A (es) 2015-12-03
KR101858913B1 (ko) 2018-05-16
CN107759594A (zh) 2018-03-06
DK2958916T3 (en) 2018-11-12
KR20170094012A (ko) 2017-08-16
BR112015019508A8 (pt) 2019-11-19
EP2958916B1 (en) 2018-09-12
RU2619944C2 (ru) 2017-05-22
PL3431475T3 (pl) 2021-09-13
TWI670269B (zh) 2019-09-01
IL240277A0 (en) 2015-09-24
MX363715B (es) 2019-03-29
US10723730B2 (en) 2020-07-28
ES2869277T3 (es) 2021-10-25
BR112015019508A2 (pt) 2017-07-18
JP2014162794A (ja) 2014-09-08
CA2900322C (en) 2019-03-26
SG11201505680RA (en) 2015-09-29
DK3431475T3 (da) 2021-05-25
PL2958916T3 (pl) 2019-01-31
HUE040434T2 (hu) 2019-03-28
KR20150107872A (ko) 2015-09-23
SI2958916T1 (sl) 2018-11-30
MX2019003605A (es) 2019-06-17
TR201816077T4 (tr) 2018-11-21
PT3431475T (pt) 2021-05-13
AU2014220354A1 (en) 2015-08-06
NZ710138A (en) 2020-09-25
JP6381016B2 (ja) 2018-08-29
CY1124068T1 (el) 2022-05-27
MX386473B (es) 2025-03-18
CA2900322A1 (en) 2014-08-28
HK1248217A1 (zh) 2018-10-12
JP2017186376A (ja) 2017-10-12
CN111253394A (zh) 2020-06-09
CY1120734T1 (el) 2019-12-11
EP3431475B1 (en) 2021-04-07
US20180065964A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
TWI633103B (zh) 選擇性ｃｄｋ４／６抑制劑之固態形式
JP6946194B2 (ja) キナーゼを調節する化合物の固体形態
JP6998969B2 (ja) （ｓ）－２－（（２－（（ｓ）－４－（ジフルオロメチル）－２－オキソオキサゾリジン－３－イル）－５，６－ジヒドロベンゾ［ｆ］イミダゾ［１，２－ｄ］［１，４］オキサゼピン－９－イル）アミノ）プロパンアミドの多形体及び固体形態と、生産方法
WO2023091974A2 (en) Salt and solid forms of (r)-1-(5-methoxy-1 h-indol-1-yl)-n,n-dimethylpropan-2-amine
EP3860981A1 (en) Niraparib salts
CN117616022A (zh) 晶形
HK40023529A (en) Solid forms of a selective cdk4/6 inhibitor
NZ710138B2 (en) Solid forms of a selective cdk4/6 inhibitor
WO2020222190A1 (en) Crystalline form of 6-[4-[1 -(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1 -yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide
WO2020222189A1 (en) Crystalline form of 6-[4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide